Investor Presentaiton

Investor presentation ADA 2019 Slide 20 In Dual VIII, mean body weight gain was 1.7 kg lower for XultophyⓇ and with lower risk of hypoglycaemia compared with glargine U100 Body weight - change from baseline Mean change body weight (Kg) 4.0 IDegLira Severe or blood glucose confirmed symptomatic hypoglycaemic episodes over 104 weeks Number of episodes glargine U100 per patient 3.4 kg 2.0 IDegLira glargine U100 3.0 2.0 1.0 0.0 1.5 1.0 1.7 kg* 0.5 0.0 -1.0 04 12 26 52 Weeks 78 104 0 8 Means from the MMRM model * statistically significant vs. insulin glargine U100 after 104 weeks; Kg: kilograms; CI: confidence interval; ETD: estimated treatment difference; IDegLira/XultophyⓇ: insulin degludec/liraglutide; glargine U100: insulin glargine U100; LS: least squares; MMRM: mixed model repeated measurement 56% rate reduction* 16 24 32 40 48 56 64 72 80 88 96 104 Weeks Severe or blood glucose confirmed symptomatic hypoglycaemia: An episode that is severe according to the American Diabetes Association classification or BG confirmed by a plasma glucose value < 3.1 mmol/L (56 mg/L) with symptoms consistent with hypoglycaemia. CI: confidence interval; conf., confirmed; ERR: estimated rate ratio; Symp: symptomatic novo nordisk

View entire presentation